We have located links that may give you full text access.
Case Reports
Journal Article
Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review.
Medicine (Baltimore) 2017 Februrary
RATIONALE: Plasmablastic lymphoma (PBL) is a rare subtype of human immunodeficiency virus (HIV)-related non-Hodgkin's lymphoma that predominantly manifests in the oral cavity.
PATIENT CONCERNS: Three cases of HIV-negative PBL were reported.
DIAGNOSES: HIV-negative PBL INTERVENTIONS:: The patient had undergone chemotherapy.
OUTCOMES: Clinical outcomes were very poor in Cases 1 and 3; Case 2, whose diagnosis suggested no bone marrow involvement, is still alive.
LESSONS SUBSECTIONS: These cases served to broaden the reported clinical spectrum of HIV-negative PBL. Clinicians and pathologists need to be familiar with lymphoma in the identified extra-oral PBL variation and there levant differential diagnosis procedures for this particular disease.
PATIENT CONCERNS: Three cases of HIV-negative PBL were reported.
DIAGNOSES: HIV-negative PBL INTERVENTIONS:: The patient had undergone chemotherapy.
OUTCOMES: Clinical outcomes were very poor in Cases 1 and 3; Case 2, whose diagnosis suggested no bone marrow involvement, is still alive.
LESSONS SUBSECTIONS: These cases served to broaden the reported clinical spectrum of HIV-negative PBL. Clinicians and pathologists need to be familiar with lymphoma in the identified extra-oral PBL variation and there levant differential diagnosis procedures for this particular disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app